Efficacy and Safety of Marstacimab in Participants With Severe Hemophilia A or B Without Inhibitors: Hemophilia Subgroup Results From the Phase 3 BASIS Trial and its Open-Label Extension

Hämostaseologie 2026

View at publisher
Authors: Christoph Male, Laurent Frenzel, Teruhisa Fujii, Tadashi Matsushita, Osman Bülent ZÜLFİKAR, Delphine Agathon, P Klaus, V Rupp, P Sun, Andrew Palladino
DOI: 10.1055/s-0045-1814575
Cited by: 0

Abstract

Introduction The phase 3 BASIS trial (NCT03938792) demonstrated the efficacy and safety of prophylaxis with marstacimab in participants (pts) with severe (factor VIII

Fields of Study & Subjects

Hemophilia Treatment and Research Platelet Disorders and Treatments Coagulation Bradykinin Polyphosphates and Angioedema

Publication details

Journal / source
Hämostaseologie
Volume
46
Issue
S 01
Pages
S55–S56
Publication date
1 February 2026
Language
DE